Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.

ABSTRACT:

Background

Although older patients are at increased risk for venous thromboembolism (VTE), thromboprophylaxis is underused because of bleeding concerns. The MARINER trial evaluated whether rivaroxaban reduced symptomatic postdischarge VTE in acutely ill medical patients.

Objectives

We hypothesized that rivaroxaban would have a favorable benefit/risk profile in patients ≥75 years of age.

Methods

Patients were randomized in a double-blind manner at hospital discharge to rivaroxaban (10 mg/day for creatinine clearance ≥50 ml/min; 7.5 mg/day for ≥30-<50 ml/min) or placebo for 45 days. Using a Cox proportional hazard model including treatment as a covariate, we compared the risk of the primary efficacy outcome (symptomatic VTE plus VTE-related death in the intention-to-tre

SUBMITTER: Ageno W 

PROVIDER: S-EPMC9292378 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature